Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
- Written by PR Newswire
![]() |
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Regor...















